key: cord-1022614-bs5up5x8 authors: Beyer, Katharina; Van Hemelrijck, Mieke; Kinsella, Netty; Barod, Ravi title: How does COVID‐19 impact treatment decision‐making for clinicians in localised kidney cancer date: 2020-11-23 journal: BJUI Compass DOI: 10.1002/bco2.57 sha: 8c5640af210afe5a86e4233ecbc2f338eadf82ec doc_id: 1022614 cord_uid: bs5up5x8 nan present different side effect profiles, 1 making appropriate treatment selection paramount to optimize quality of life. The COVID-19 pandemic has complicated the process of decision making. Official guidance called for non-urgent cancer care to be rationed, delayed and/or adapted. Hence, the British Association of Urological Surgeons (BAUS) recommended that patients diagnosed with localized KC were offered a period of surveillance rather than curative treatment. 2 The impact of COVID-19 medical guidance on patients was described by kidney patient associations in the United States and United Kingdom (KCCURE and KCUK) in small snapshot surveys, exploring patient experience, anxiety, and their management. 3, 4 They found that anxiety was high in respect to both cancer and COVID-19 and its implications for treatment and follow-up. Building on these initial observations, we conducted a cross-sec- The opportunity to connect with the wider team is a unique experience with virtual MDTs possibly leading to a loss of professional understanding and social interaction. With respect to treatment during Covid-19, the EAU Guidelines Office Rapid Response Group is recommending postponement of surgery by 6 months where progression is unlikely. 6 Fifty-eight percent of UK respondents reported that deferring treatment for 0-12 months for T1a disease or deferring treatment for 3-6 months in T1b disease (53% of respondents) or a delay of 0-6 month for T2 lesions (83% of respondents) would adversely affect the oncological outcomes. This might also in part explain the high level of dissatisfaction in respect to available treatment options, where none of the UK nurses who responded and only 28% of UK doctors were satisfied with the treatment options. The UK's deferred treatment plan was reported by the respondents as a contributor to HCP dissatisfaction. Only 36% of UK respondents were able to perform partial nephrectomies and 8% ablation. As reported by KCCURE's and KCUK's snapshot surveys, patients reported experiencing a high level of anxiety during the COVID-19 period. Therefore, it is not surprising that 47% of UK respondents confirmed an increase in the number of patients contacting their service. This, combined with widespread re-deployment of health care professionals (56% of the medical team and 81% of the nursing team) may explain the reason why only 47% of UK nurses and doctors felt satisfied to very satisfied with the service they provided during the peak of the pandemic. With a demonstrable increase in cancer patient anxiety, 3,4 consideration should, hence, be given to the merits of staff redeployment versus patient safety if a second wave pandemic was realized. For the delivery of future KC care, 78% of UK respondents agreed there is a need for additional imaging (78%), theatre (100%), inpatient (78%), outpatient capacity (69%) and manpower resources (58%). Responding to the additional needs will be challenging, but necessary. 5 This includes a stratified approach to patient assessment in relation to anxiety and depression, as a result of the increase in waiting times. Moreover, both doctors and nurses reported a high level of moral distress. 67% of respondents felt distressed to worst possible distress. This should be taken seriously by policy makers and hospital executives going forward. A limitation was the distribution of the survey via twitter, however the CHERRIES statement, which aims to reduce selection bias, guided our understanding of the sample (self)selection (see online Appendix). 8 Our survey has shown high levels of dissatisfaction among HCPs regarding the standard of care delivered during the COVID-19 pandemic in the United Kingdom, suggesting that there is a need to re-visit the guidelines. It is important to ensure the diagnostic pathway is not disrupted, ensure the ability to use video consultations is available, prevent the medical team and particularly CNSs to be redeployed and all available treatment options such as the ability to perform surgery in COVID-19 cold sites are assured. Our findings should be used to inform policy on KC care provision in the event of a second wave or a future healthcare crisis. Grants were received from Kidney Cancer UK and the Royal Marsden Charity. https://orcid.org/0000-0002-8450-8850 Mieke Van Hemelrijck https://orcid.org/0000-0002-7317-0858 British Association of Urological Surgeons. COVID-19 Strategy for the Interim Management of Kidney Cancer Prepared by the BAUS Section of Oncology. British Association of Urological Surgeons COVID-19/Kidney Cancer Patient Survey online The impact of COVID-19 on kidney cancer patients online The impact of COVID-19 outbreak on uro-oncological practice across Europe: Which burden of activity are we facing ahead? Selecting the most appropriate oncological treatment for patients with renal masses during the COVID-19 pandemic: recommendations from a referral center Telemedicine online visits in urology during the COVID-19 pandemic-potential, risk factors, and patients' Perspective Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES)